Post-exposure HIV prophylaxis adherence to full 28-day course versus weekly therapy in Tehran
1
Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Department of Infectious Diseases, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2
Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
3
Community Medicine Department, Medical Faculty, Mazandaran University of Medical Sciences, Sari, Iran
Submission date: 2022-01-18
Final revision date: 2022-04-06
Acceptance date: 2022-04-08
Online publication date: 2024-05-18
Corresponding author
SeyedAhmad SeyedAlinaghi
Prof. SeyedAhmad SeyedAlinaghi, Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran, e-mail: s.a.alinaghi@gmail.com
Prof. SeyedAhmad SeyedAlinaghi, Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran, e-mail: s.a.alinaghi@gmail.com
HIV & AIDS Review 2024;23(2):173-177
KEYWORDS
TOPICS
ABSTRACT
Background:
This randomized clinical study was conducted to compare the adherence of post-exposure human immunodeficiency virus (HIV) prophylaxis (PEP) in full 28-day course of antiretroviral (ARV) treatment versus weekly therapy, and to find reasons for insufficient compliance among people referred to HIV clinic of Imam Khomeini Hospital, a teaching, and referral university hospital in Tehran, from 2018 to 2019.
Material and methods:
This study determined the most suitable PEP protocol between full 28-day and weekly courses. After obtaining informed consent from 293 participants with exposure to HIV (both sexual and non-sexual), 106 and 111 individuals were randomly divided into two groups of a 28-day course and weekly PEP protocol, respectively, by simple randomization method, and the remaining 76 persons were lost to follow-up during the study. Adherence to PEP was defined as taking 95% of the prescribed antiretroviral therapy (ART) in each group. Chi-square test (Fisher exact test) and t-test were performed using SPSS software considering other variables, including age, gender, marital status, educational level, occupation, and distance from work or residence to a hospital.
Results:
After analyzing data and possible factors affecting treatment adherence, it was found that 28-day PEP protocol increased ARV compliance (OR = 4.14; 95% CI: 1.79-9.58%; p = 0.001) compared with weekly protocol. Furthermore, no associations between adherence and demographic characteristics, such as gender, age, education level, occupation, income, marital status, and factors, including distance from people's place of residence or work, were found.
Conclusions:
Adherence to PEP was much higher in the 28-day protocol than the weekly course of treatment.
This randomized clinical study was conducted to compare the adherence of post-exposure human immunodeficiency virus (HIV) prophylaxis (PEP) in full 28-day course of antiretroviral (ARV) treatment versus weekly therapy, and to find reasons for insufficient compliance among people referred to HIV clinic of Imam Khomeini Hospital, a teaching, and referral university hospital in Tehran, from 2018 to 2019.
Material and methods:
This study determined the most suitable PEP protocol between full 28-day and weekly courses. After obtaining informed consent from 293 participants with exposure to HIV (both sexual and non-sexual), 106 and 111 individuals were randomly divided into two groups of a 28-day course and weekly PEP protocol, respectively, by simple randomization method, and the remaining 76 persons were lost to follow-up during the study. Adherence to PEP was defined as taking 95% of the prescribed antiretroviral therapy (ART) in each group. Chi-square test (Fisher exact test) and t-test were performed using SPSS software considering other variables, including age, gender, marital status, educational level, occupation, and distance from work or residence to a hospital.
Results:
After analyzing data and possible factors affecting treatment adherence, it was found that 28-day PEP protocol increased ARV compliance (OR = 4.14; 95% CI: 1.79-9.58%; p = 0.001) compared with weekly protocol. Furthermore, no associations between adherence and demographic characteristics, such as gender, age, education level, occupation, income, marital status, and factors, including distance from people's place of residence or work, were found.
Conclusions:
Adherence to PEP was much higher in the 28-day protocol than the weekly course of treatment.
REFERENCES (16)
1.
Spira AI, Marx PA, Patterson BK, Mahoney J, Koup RA, Wolinsky SM, Ho DD. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 1996; 183: 215-225.
2.
World Health Organization. Guidelines on post-exposure prophylaxis for HIV. Recommendations for a public health approach. Geneva: WHO; 2014.
3.
Blashill AJ, Ehlinger PP, Mayer KH, Safren SA. Optimizing adherence to pre-exposure and postexposure prophylaxis: the need for an integrated biobehavioral approach. Clin Infect Dis 2015; 60 Suppl 3: S187-190.
4.
Forda N, Irvinea C, Shubberb Z, Baggaleya R, Beanlanda R, Vitoriaa M, et al. Adherence to HIV post-exposure prophylaxis: a systematic review and meta-analysis. AIDS 2014, 28: 2721-2727.
5.
SeyedAlinaghi S, Taj L, Mazaheri-Tehrani E, Ahsani-Nasab S, Abedinzadeh N, McFarland W, et al. HIV in Iran: onset, responses, and future directions. AIDS 2021; 35: 529-542.
6.
Dominguez KL, Smith DK, Vasavi T, Crepaz N, Lang K, Heneine W, et al. Updated guidelines for antiretroviral post-exposure prophylaxis after sexual, injection drug use, or other non-occupational exposure to HIV – the United States. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; 2016.
7.
Hadadi A, Rasoulinezhad M, Jamali S, Seyed Ali Naghi SA, Paydari K, Boyer MA, et al. Adherence to antiretroviral prophylaxis after occupational and non-occupational exposure to human immunodeficiency virus in patients consulting the voluntary counseling and testing center of Imam Khomeini Hospital, Tehran, 2008-2009. Journal of School of Public Health and Institute of Public Health Research 2012; 9: 37-44.
8.
Rasoolinejad M, Naghib Sadat B, Najafi Z, Baesi K, Heidari H, Seyedalinaghi S. Epidemiological and clinical information of people at risk for HIV referred to the voluntary counseling and testing center, Tehran, Iran, 2013-2014. J Int Transl Med 2018; 6: 176-180.
9.
Chacko L, Ford N, Sbaiti M, Siddiqui R. Adherence to HIV post-exposure prophylaxis in victims of sexual assault: a systematic review and meta-analysis. Sex Transm Infect 2012; 88: 335-341.
10.
Malinverni S, Libois A, Gennotte AF, La Morté C, Mols P. Prescription of non-occupational post-exposure HIV prophylaxis by emergency physicians: an analysis on accuracy of prescription and compliance. PLoS One 2016; 11: e0153021. DOI: https://doi.org/10.1371/journa....
11.
Malinverni S, Gennotte AF, Schuster M, De Wit S, Mols P, Libois A. Adherence to HIV post-exposure prophylaxis: a multivariate regression analysis of a 5 years prospective cohort. J Infect 2018; 76: 78-85.
12.
Tetteh RA, Nartey ET, Lartey M, Mantel-Teeuwisse AK, Leufkens HGM, Nortey PA, Dodoo ANO. Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana. BMC Public Health 2015; 15: 573. DOI: https://doi.org/10.1186/s12889....
13.
Niakan S, Mehraeen E, Noori T, Gozali E. Web and mobile based HIV prevention and intervention programs pros and cons – a review. Stud Health Technol Inform 2017; 236: 319-327.
14.
Thomas R, Galanakis C, Vézina S, Longpré D, Boissonnault M, Huchet E, et al. Adherence to post-exposure prophylaxis (PEP) and incidence of HIV seroconversion in a major North American cohort. PLoS One 2015; 10: e0142534. DOI: 10.1371/ journal.pone.0142534.
15.
Ford N, Venter F, Irvine C, Beanland RL, Shubber Z. Starter packs versus full prescription of antiretroviral drugs for post exposure prophylaxis a systematic review. Clin Infect Dis 2015; 60 (Suppl 3): S182-S186.
16.
Zimmer R. HIV post-exposure prophylaxis starter packs were not designed to help or hinder adherence. Clin Infect Dis 2016; 62: 667-668.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
